Lipella Pharmaceuticals asset sale in Chapter 11
Lipella Pharmaceuticals Inc. is operating under Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the Western District of Pennsylvania, Case No. 26-20879-CMB, after filing a voluntary petition on March 30, 2026.
Rhea-AI Filing Summary
Lipella Pharmaceuticals Inc. is operating under Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the Western District of Pennsylvania, Case No. 26-20879-CMB, after filing a voluntary petition on March 30, 2026.
On May 14, 2026, the company entered into an Asset Purchase Agreement with XRAIY under which XRAIY agreed to purchase substantially all of Lipella’s assets. The Bankruptcy Court authorized and approved this sale and the Asset Purchase Agreement pursuant to section 363 of the Bankruptcy Code by order dated June 4, 2026, with the order and agreement provided as exhibits.
The company cautions that trading in its common stock while the Chapter 11 case is pending is highly speculative and poses substantial risks, and that trading prices may bear little or no relationship to the actual recovery, if any, by holders of its common stock.
Positive
- None.
Negative
- Filed a Chapter 11 case and agreed to sell substantially all assets under an Asset Purchase Agreement with XRAIY, with the sale approved by the Bankruptcy Court pursuant to section 363 of the Bankruptcy Code.
- Warns that common stock trading is highly speculative, noting prices may bear little or no relationship to the actual recovery, if any, by holders of common stock during the Chapter 11 case.
8-K Event Classification
3 items: 1.01, 1.03, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 1.03
Bankruptcy or Receivership
Business
The company or a significant subsidiary has filed for bankruptcy or entered receivership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Chapter 11 filing date: March 30, 2026
Asset Purchase Agreement date: May 14, 2026
Sale Order date: June 4, 2026
+2 more
5 metrics
Chapter 11 filing date
March 30, 2026
Voluntary petition for relief under chapter 11 filed in U.S. Bankruptcy Court
Asset Purchase Agreement date
May 14, 2026
Agreement with XRAIY to purchase substantially all company assets
Sale Order date
June 4, 2026
Bankruptcy Court authorized the sale and Asset Purchase Agreement under section 363
Bankruptcy case number
26-20879-CMB
Case in the U.S. Bankruptcy Court for the Western District of Pennsylvania
Sale Order docket number
Doc. No. 115
Order approving the section 363 sale of substantially all assets
Key Terms
Asset Purchase Agreement, chapter 11, section 363 of the Bankruptcy Code, Encumbrances, +1 more
5 terms
Asset Purchase Agreement financial
"entered into an Asset Purchase Agreement with XRAIY"
An asset purchase agreement is a legal contract in which a buyer agrees to buy specific assets and contracts of a business rather than buying the company’s stock or ownership. It matters to investors because it determines exactly what is being bought and what liabilities stay behind — like buying the furniture and equipment from a store but not the building or past debts — which affects the deal’s value, taxes and future risk exposure.
chapter 11 regulatory
"filed a voluntary petition for relief under chapter 11 of title 11"
Chapter 11 is a U.S. bankruptcy process that lets a financially distressed company keep operating while it reorganizes its debts and business plan under court supervision. Think of it as a formal pause that allows the company to renegotiate payments, shed contracts or assets, and seek a path to profitability instead of being liquidated; investors watch it because it can change the value and priority of claims, equity dilution, or the likelihood of recovery.
section 363 of the Bankruptcy Code regulatory
"approved the Sale and the Asset Purchase Agreement, pursuant to section 363 of the Bankruptcy Code"
Encumbrances regulatory
"Authorizing the Sales Free and Clear of all Encumbrances"
Encumbrances are legal claims, liens, pledges or other restrictions attached to an asset that limit its use, sale or the amount of value that can be obtained from it. For investors they matter because encumbrances reduce an asset’s effective worth and can complicate ownership or financing—like buying a house that still has a mortgage or a lien, which lowers what you can keep or borrow against the property.
Executory Contracts regulatory
"Authorizing the Assumption and Assignment of Certain Executory Contracts"
FAQ
What Chapter 11 bankruptcy case has Lipella Pharmaceuticals (LIPO) filed?
Lipella Pharmaceuticals has filed a voluntary Chapter 11 case in the U.S. Bankruptcy Court for the Western District of Pennsylvania, under Case No. 26-20879-CMB, placing the company into court-supervised reorganization proceedings.
What is the Asset Purchase Agreement between Lipella (LIPO) and XRAIY?
Lipella entered into an Asset Purchase Agreement with XRAIY on May 14, 2026, under which XRAIY agreed to purchase substantially all of Lipella’s assets. The detailed agreement is attached as an exhibit to the company’s disclosure.
What has the Bankruptcy Court approved for Lipella Pharmaceuticals (LIPO)?
The Bankruptcy Court issued a Sale Order on June 4, 2026, authorizing and approving the sale of substantially all of Lipella’s assets to XRAIY and approving the Asset Purchase Agreement under section 363 of the Bankruptcy Code.
How does Lipella (LIPO) describe the risk of trading its common stock?
Lipella states that trading in its common stock during the Chapter 11 case is highly speculative and poses substantial risks, and that trading prices may bear little or no relationship to the actual recovery, if any, for common shareholders.
When did Lipella (LIPO) file for Chapter 11 and when was the sale approved?
Lipella filed its voluntary Chapter 11 petition on March 30, 2026. The Bankruptcy Court then approved the section 363 sale of substantially all assets to XRAIY by order dated June 4, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
